What Histrine Treats: Main Uses and Benefits

The primary therapeutic role of Histrine is to provide supportive symptomatic relief for conditions associated with heightened physiological activity. This medicine is commonly used to help manage symptoms related to seasonal and perennial allergic rhinitis and chronic hives.

Addressing Symptomatic Discomfort and Acute Episodes

Histrine is applied in clinical settings where short-term symptomatic assistance is needed to address acute episodes and symptom clusters that interfere with daily functioning. This is relevant for managing symptom clusters related to the upper respiratory tract and localized skin irritation. The use is considered relevant in contexts marked by temporary physiological imbalance.

“It provides supportive relief when symptoms intensify and helps patients cope more steadily during difficult episodes.”

Support for Fluctuating Symptom Patterns

The medication is also relevant for managing conditions characterized by periods of heightened symptoms that involve episodic or fluctuating manifestations, especially recurrent skin conditions. By offering supportive relief, Histrine assists with easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Histrine, which contains the active ingredient cetirizine, is generally suitable for most adults and children from a certain age, primarily for the treatment of seasonal or perennial allergies and chronic hives.

Before taking Histrine, it is important to be aware of certain conditions or situations where its use may be contraindicated, require dose adjustment, or warrant professional medical advice.

Who Can Use Histrine?

• Adults and adolescents with allergic symptoms or chronic hives.
• Children aged 6 years and older, with lower doses often used for children aged 2 to 5 years (always follow specific product guidelines and pediatrician advice for pediatric dosing).

Who Should Not Use Histrine?

Histrine is contraindicated and should not be used by individuals with:

• Known allergy or hypersensitivity to cetirizine, hydroxyzine, or any other ingredients in the product formulation.
• Severe kidney impairment (end-stage renal disease or very low creatinine clearance).

Special caution and potential dose adjustment are required for individuals with:

• Mild to moderate kidney impairment or liver disease (a lower daily dose is typically recommended).
• Pregnant or breastfeeding women (consultation with a healthcare provider is essential, as the drug passes into breast milk).
• Older adults (may be more susceptible to side effects like drowsiness, and kidney function should be considered).

Additionally, alcohol consumption should be avoided while taking Histrine due to the potential for increased drowsiness or central nervous system effects. Individuals should also use caution when performing tasks that require mental alertness, such as driving or operating machinery, until they know how the medication affects them.

Interactions with other medicines and products

Official regulatory information for Histrine (Cetirizine Hydrochloride) documents specific pharmacodynamic and pharmacokinetic interactions that may alter its effects or systemic exposure. No medicinal product combinations are formally classified as contraindicated.

Documented Pharmacodynamic Interactions

Concurrent use with Alcohol and other CNS Depressants (including sedatives and tranquilizers) is cautioned against due to the risk of additional reductions in alertness and further impairment of CNS performance. This represents an officially recognized additive pharmacodynamic effect. Separately, co-administration with Pitolisant may formally diminish the therapeutic efficacy of Pitolisant.

Documented Pharmacokinetic Interactions

Co-administration with Theophylline (specifically at 400 mg once daily) results in a 16% decrease in the clearance of cetirizine, leading to increased exposure of Histrine. Furthermore, the drug is recognized as a P-glycoprotein (P-gp) substrate, an interaction relevant when co-administered with P-gp inhibitors like Verapamil. Studies confirm that Food intake does not affect the overall extent of exposure (AUC), but the time to reach peak concentration (Tmax) is delayed by approximately 1.7 hours. No clinically significant interactions were observed with common agents like Azithromycin or Erythromycin.

Population-Specific Notes

Patients with Hepatic or Renal Impairment are noted to have decreased drug clearance of cetirizine, which alters systemic exposure and requires consideration.

Histrine is an antagonist (inhibitor) of the Histamine H3 Receptor (H3R) in the central nervous system.

The H3R typically functions as a presynaptic autoreceptor on histaminergic neurons, mediating negative feedback that suppresses histamine release, and as a heteroreceptor on non-histaminergic neurons, modulating the release of other neurotransmitters (e.g., acetylcholine, norepinephrine).

By blocking the H3R, Histrine prevents the receptor's inhibitory action on the histaminergic neuron. This disinhibition facilitates neurotransmission, resulting in increased neuronal histamine release into the synaptic cleft. The elevated histamine, acting on H1 receptors, along with the modulated output of other neurotransmitters, contributes to the upregulation of activity within arousal-promoting neural pathways. The core pharmacodynamic action is the modulation of H3R-mediated neuronal inhibition, with Histrine exhibiting low affinity for H1 and H2 receptors.

Official Administration Instructions for Histrine

The Histrine formulation is administered by the oral route (tablet, capsule, or liquid) once daily. It should be taken at approximately the same time each day and may be taken with or without food. Adherence to the prescribed frequency and specific dosage limitations is essential, and patients must not exceed the stated maximum daily amount.

Official Dosing and Administration Rules

Procedural Steps and Missed Doses

Preparation: Liquid formulations (syrup, drops) require careful measurement using only the calibrated dosing device provided. Tablets and capsules should be swallowed whole with fluid; orally disintegrating tablets should be placed directly on the tongue to dissolve and swallowed with saliva.

Missed Dose: If a dose is forgotten, the official instruction is to take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Do not double the dose to catch up.

This protocol ensures consistent daily systemic exposure, with flexibility in relation to meals, while mandating critical dose adjustments to account for age and reduced kidney function.

Research evidence / Overview of Studies for Histrine

The evidence base for Histrine (Cetirizine) is derived primarily from clinical research, including randomized controlled trials and systematic reviews, which describe the structure and outcomes measured, focusing on changes in patient-reported symptoms and disease activity.

Evidence for Allergic Rhinitis (SAR and PAR)

Research exploring how symptoms change over time in Seasonal (SAR) and Perennial (PAR) Allergic Rhinitis has primarily used short-term to medium-term randomized controlled trials (RCTs). Studies were conducted during periods of increased symptom activity and examined outcomes related to physical discomfort, such as changes in the Total Symptom Severity Complex (TSSC). The evidence base includes studies of adults and pediatric patients. While research provides insight into short-term changes, long-term effects on the continuous management of these conditions across multiple seasons are not fully established by randomized efficacy trials.

Evidence for Chronic Hives (Chronic Idiopathic/Spontaneous Urticaria)

The research for Chronic Hives involves controlled studies that examined outcomes linked to irritative states, focusing on reduction in the number and severity of hives (wheal count) and the intensity of itching. Studies monitored symptomatic changes for periods of several months. Research has also explored doses higher than the standard study dose. Findings indicate patterns related to the monitored outcomes for standard dosing. However, the evidence for high-dose strategies in pediatric patients remains insufficient, and the quality of evidence varies across studies.

Evidence Gaps and Follow-up Limitations

The majority of efficacy data for Histrine is relevant in trials assessing short-term or episodic symptom patterns. Follow-up durations were limited in the primary controlled trials, and longer observation periods were mainly designed to gather safety data. Data for certain groups, such as older adults, remain insufficient within the primary efficacy trials. Research describes group patterns, not personal outcomes.

Key Studies & References

1. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
2. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
3. Label: CETIRIZINE HYDROCHLORIDE tablet, film coated - DailyMed - NIH
4. Cetirizine: MedlinePlus Drug Information

Official Storage and Handling Requirements

Histrine (cetirizine hydrochloride) must be stored at a Controlled Room Temperature between 20°C and 25°C (68°F and 77°F), as specified in official labeling. The medication must be kept away from excessive heat above 40°C and high humidity to maintain stability. Oral solutions require additional protection from light.

All forms of the medication must be kept in the original container, which should be tightly closed. The labeling explicitly states that the product must be stored out of the reach of children.

Disposal

Official disposal instructions require that any unused or expired Histrine product be disposed of in accordance with local requirements. In the event of an overdose or accidental ingestion, immediate contact with a Poison Control Center is mandatory.